Best CDMOs in India — Ranked by Signal Score · 2026

· updated as new inspection, certificate, and trial data enters the platform
USA Europe Asia UK India Switzerland Germany South Korea Japan China
11
CDMOs in region
11
Fully scored
4
With FDA records
14
FDA inspections
21
EMA/MHRA GMP certs

CDMO Signal tracks 11 biopharma CDMOs with confirmed India manufacturing facilities, of which 11 are fully scored across the four-pillar composite Signal Score. Across all modalities, Piramal Pharma Solutions, Syngene International, and Biocon Biologics lead the India ranking by composite score. Signal Score integrates FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. For modality-specific rankings within India — AAV, cell therapy, biologics, and 10 other tracked modalities — see the modality-region breakdown below. Full methodology at cdmosignal.com/methodology.

India-based CDMOs ranked by CDMO Signal's composite Signal Score, filtered to manufacturers with confirmed Indian facilities. India is one of the top three global CDMO manufacturing countries by volume, spanning oral solids, biologics, sterile injectables, and increasingly advanced-therapy platforms. Indian CDMOs range from domestic-market-focused to fully global with FDA + EMA + MHRA cross-jurisdictional certification. The ranking includes any CDMO with an Indian manufacturing site — filtering is derived from each CDMO's declared facility locations.

# CDMO Signal Score Quality FDA · GMP Capacity Programs
1
PR
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
 83.3 95.0 5 insp · 13 GMP — 0 programs
2
SG
Syngene International
Bengaluru, India
 78.5 96.3 2 insp · 0 GMP — 0 programs
3
BC
Biocon Biologics
Bengaluru, India
 77.6 97.1 4 insp · 2 GMP — 0 programs
4
GZ
Genezen
Indianapolis, IN · Lexington, MA
 71.5 85.8 3 insp · 0 GMP Available 0 programs
5
IU
Indiana University Vector Production Facility
Indianapolis, IN
 66.3 — — — 49 programs
6
SI
Simtra BioPharma Solutions
Bloomington, IN · Halle, DE
 65.7 73.3 0 insp · 1 GMP — 0 programs
7
AU
Aurigene Pharmaceutical Services
Hyderabad, India
 63.0 — — — 0 programs
8
SS
Singota Solutions
Bloomington, IN
 59.0 — — — 0 programs
9
CLB
Clara Biotech
Indianapolis, IN
 56.5 — — — 0 programs
10
IC
INCOG BioPharma Services
Fishers, IN
 56.5 — — — 0 programs
11
IP
Intas Pharmaceuticals
Ahmedabad, India
 51.4 45.5 0 insp · 5 GMP — 0 programs
How we score CDMOs →

How do Indian CDMOs compare to Chinese and Korean alternatives on regulatory posture?

Indian CDMOs have historically led Asian peers in FDA inspection density — the FDA maintains a large inspection presence in India and Indian pharmaceutical exports to the US are among the highest globally. That translates to Indian CDMOs typically holding more FDA inspections on record than Chinese or Korean counterparts of comparable size. That said, inspection density is not the same as inspection outcome — the Signal Score's Quality Compliance pillar weights the classification (NAI/VAI/OAI), not just the count. Sponsors comparing Asian CDMOs should focus on the specific facility's inspection outcome record, not the country-aggregate; individual profile pages surface facility-level detail.

Which Indian CDMOs handle biologics and advanced therapy modalities?

India's CDMO base has traditionally been strongest in small molecules and oral solid dosage forms, but the biologics and advanced-therapy footprint has grown substantially. Notable capabilities exist across mAb manufacturing, biosimilar production, and increasingly viral vector + cell therapy. Cross-reference with modality pages to filter Indian CDMOs by capability class: biologics, mRNA, cell therapy, or the gene therapy umbrella. Individual CDMO profile pages surface the specific modality capabilities on file.

US and EU regulatory considerations for India-manufactured drug supply

Indian CDMOs supplying US markets need active FDA registrations and pre-approval inspection posture; the FDA has been publicly focused on Indian generic pharmaceutical quality for years, and inspection outcomes there materially affect commercial supply eligibility. EU supply requires EMA GMP certification with an EU-based Qualified Person for batch release, which for Indian-manufactured material requires either an EU-based CDMO partner for release or an in-house EU QP arrangement. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly, so Indian CDMOs with cross-jurisdictional posture rank higher on this pillar than domestic-market-only competitors.

Browse by modality within India

Modality-specific rankings for India-manufactured programs. Each page filters the modality's global ranking to CDMOs with confirmed India facilities.

AAV / Gene Therapy (2) Lentiviral Vector (2) Cell Therapy (4) Biologics / mAb (6) Oligonucleotide / ASO (1) Exosome / Extracellular Vesicle (1) ADC (Antibody-Drug Conjugate) (1) Gene Therapy (2) Cell & Gene Therapy (6) Viral Vector (2)
Other regions
CDMOs in United States CDMOs in Europe CDMOs in Asia CDMOs in United Kingdom CDMOs in Switzerland CDMOs in Germany CDMOs in South Korea CDMOs in Japan CDMOs in China